Study shows that maintenance rituximab is useful for advanced indolent lymphoma

A new study has found for the first time that maintenance therapy with the novel antibody, rituximab (MR) following cyclophosphamide, vincristine and prednisone (CVP) therapy improves progression-free survival in patients with stage III-IV indolent lymphoma, according to Howard S. Hochster, M.D. of NYU Langone Medical Center, lead author of a recent study published online ahead of print in the Journal of Clinical Oncology.

Read the whole article on Physorg

More from Physorg